Prophylaxis and treatment of venous thromboembolism: The role of new antithrombotic drugs;Nuovi farmaci antitrombotici per la profilassi e la terapia del tromboembolismo venoso

Recenti Progressi in Medicina

Volumn 96, Issue 4, 2005, Pages 196-204

  Falciani, Michela ^a   Imberti, Davide ^a,b   Prisco, Domenico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Ospedale di Piacenza   (Italy)

Author keywords

Anticoagulants; Antithrombotic drugs; Fondaparinux; Heparins; Idraparinux; Venous thromboembolism; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; THROMBIN INHIBITOR; THROMBOPLASTIN; XIMELAGATRAN;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; HUMAN; PROPHYLAXIS; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; FIBRINOLYTIC AGENTS; HUMANS; OLIGOSACCHARIDES; POLYSACCHARIDES; THROMBOEMBOLISM;

EID: 22844445023     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lee A, Agnelli G, Buller HR, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
2. Kearon C, Comp P, Douketis J, et al. A dose-response study of a recombinant soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J Thromb Haemost 2003; suppl:OC330.
3. Lassen MR, Bauer KA, Erksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison (Ephesus Study). Lancet 2002; 359: 1715-20.
4. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison (Pentathlon 2000 Study). Lancet 2002; 359: 1721-6.
5. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
6. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. N Engl J Med 2001; 345: 1298-304.
7. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
8. Eriksson BI, Lassen MR & The Pentasaccharide in Hip Fracture Surgery Plus (PENTHIFRAPLUS) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 2003; 163: 1337-42.
9. Agnelli G, Bergqvist D, Cohen A. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study. J Thromb Haemost 2003; suppl: OC006.
10. Cohen AT, Gallus AS, Lassen MR et al. Fondaparinux vs placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J Thromb Haemost 2003; suppl: P2406.
11. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F et al for the MATISSE Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. Ann Intern Med 2004; 140: 867-73.
12. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
13. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in DVT: a phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
14. Lassen MR, Davidson BL, Gallus A et al. A phase II randomized, double-blind, five-arm, parallel group, dose-response study of a new oral directly-acting Factor-Xa inhibitor, Razaxaban, for prevention of deep vein thrombosis in knee replacement surgery- on behalf of the Razaxaban Investigators. Blood 2003; 102: 11 suppl: 41.
15. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939- an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 1-8.
16. Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7.
17. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of VTE after total hip or knee joint replacement: the METHRO III study. Thromb Haemost 2003; 89: 288-96.
18. Eriksson BI, Agnelli G, Cohen AT, et al. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of VTE in total hip or total knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.
19. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21.
20. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1: 2119-30.
21. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty. Ann Intern Med 2002; 137: 648-55.
22. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-12.
23. Colwell C, Berkowitz-SD, Comp PC, et al. Randomized, double-blind comparison of Ximelagatran, an oral direct thrombin inhibitor, and Warfarin to prevent venous thromboembolism (VTE) after Total knee replacement (TKR) EXULT-B. Blood 2003b; 102: 11 suppl 39.
24. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7.
25. Wahlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002; 107: 93-9.
26. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomised trial. JAMA 2005; 293: 681-9.
27. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
28. Eriksson BI, Dahl OE, Ahnelf L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 1573-80.
29. Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomised trial. J Thromb Haemost 2005; 3: 103-11.